Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, WI, and began work on customer programs. The expansion more than doubled overall CGMP-scale capacity, increasing the number of manufacturing suites at the site to five.   Catalent announced plans to add two new mammalian cell culture suites at the Madison site in January 2019. Each new suite includes a 2×2,000-liter single-use bioreactor system capable ...